FGEN Stock Analysis: Buy, Sell, or Hold?
FGEN - FibroGen, Inc
$9.71
0.69 (7.65%)
â˛
5d:
+11.61%
30d:
+16.57%
90d:
-12.29%
WAIT
LOW Confidence
Analysis Updated: Jan 7, 2026 12:00 AM ET
Get Alerted When FGEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: FGEN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: FGEN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: FGEN is currently trading at $9.71, which is considered fair based on recent price action.
Technical Outlook: Technically, FGEN is in a strong downtrend. The price is approaching resistance at $9.75. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 7.6% recently.
Market Sentiment: FGEN scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $43.00 (+342.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, FGEN is in a strong downtrend. The price is approaching resistance at $9.75. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 7.6% recently.
Market Sentiment: FGEN scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $43.00 (+342.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
43/100
(HOLD)
Volume Confirmation
UNKNOWN
Confidence Score
86.8%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: Strong upward momentum (+7.6%)
- BULLISH: Trading 342.8% below Wall St target ($43.00)
- WARNING: Composite score 43/100 in the bottom quintile â this cohort historically lags the market
Support & Resistance Levels
Support Level
$8.36
Resistance Level
$9.75
Current Trend
Strong Downtrend
Technical data as of
Jan 7, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.81
Wall Street Target
$43.00
(+342.8%)
Revenue Growth (YoY)
774.8%
Earnings Growth (YoY)
53.6%
Profit Margin
2598.9%
Share & Embed Analysis
Last updated: August 23, 2026 3:42 PM ET
Data refreshes hourly during market hours. Next update: 4:42 PM
Data refreshes hourly during market hours. Next update: 4:42 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FGEN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 41 HOLD |
